A Phase IIIB Randomized, Double-Masked, Active Controlled, Dose Ranging, Multi-Center Comparative Trial in Parallel Groups, to Compare the Safety and Efficacy of Intravitreal Injections of EYE001 (Pegaptanib Sodium Macugen) Given every 6 weeks to PDT with

  • Ambati, Jayakrishna (PI)

Grants and Contracts Details

StatusFinished
Effective start/end date3/17/04 → 6/30/04